Sagent Pharmaceuticals Partners with Provepharm to Launch Bludigo, First FDA-Approved Injectable Indigo Carmine Diagnostic Dye
核心洞察
Sagent Pharmaceuticals has entered the $200 million U.S. diagnostic dye market through a strategic partnership with Provepharm (搜索) to commercialize Bludigo, the first and only FDA-approved injectable indigo carmine diagnostic dye.
The collaboration marks Sagent's expansion into the urology space, with Bludigo serving as a visualization aid for cystoscopic evaluation of ureter integrity in adults following urological and gynecological procedures.
Provepharm (搜索) is repositioning its business model to focus on innovative surgical dyes, particularly fluorescence-guided surgery solutions, with plans to launch two additional diagnostic dyes as early as 2026.
Sagent Pharmaceuticals has announced a strategic partnership with French pharmaceutical company Provepharm (搜索) to commercialize three innovative diagnostic dyes, beginning with the immediate launch of Bludigo (indigotindisulfonate sodium), an indigo carmine injection. This collaboration marks Sagent's entry into the fast-growing U.S. diagnostic dye market, valued at greater than $200 million according to IQVIA data from September 2025.
Strategic Market Entry
The partnership represents a significant expansion for Sagent, which will assume full commercial responsibility for Bludigo, the first and only FDA-approved injectable indigo carmine diagnostic dye. This product enhances Sagent's presence in the urology space by providing healthcare professionals with a cutting-edge visualization aid for cystoscopic evaluation of ureter integrity in adults following urological and gynecological procedures.
"This partnership represents a significant milestone in our long-term strategy to expand into specialty adjacencies and bring differentiated solutions to our customers," said Vishy Chebrol, CEO of Sagent. "Bludigo and the broader diagnostic dye portfolio are strong strategic fits, and we look forward to partnering with Provepharm (搜索) to deliver high quality products to clinicians and patients across the U.S."
Provepharm's Strategic Repositioning
Provepharm (搜索) is simultaneously announcing its strategic and operational repositioning toward the design, production, and supply of innovative dyes for surgical use, particularly in fluorescence-guided surgery. The company is optimizing its business model to accelerate growth in the U.S. and other international markets, leveraging its 25 years of expertise in organic chemistry.
Michel Féraud, CEO and Founder of Provepharm (搜索), emphasized the strategic value of the partnership: "We are pleased to partner with Sagent on the commercialization of Bludigo, one of Provepharm's key innovations. Sagent's proven expertise and strong market presence make them an ideal partner to bring this important product to more patients and providers."
Pipeline and Future Developments
Beyond Bludigo, the partnership establishes a framework for future commercialization of two additional diagnostic dyes from Provepharm (搜索)'s pipeline, scheduled for launch as early as 2026. These innovations aim to meet surgeons' growing needs in precision medicine and minimally invasive surgery for more efficient patient care.
Provepharm (搜索) plans to leverage its R&D capabilities to create next-generation medical dyes supporting precision surgery, including a scientific platform dedicated to fluorescence technology. The company intends to develop increasingly selective "Smart Dyes" as patented proprietary medicinal products.
Market Dynamics and Growth Drivers
The medical dye solutions market demonstrates sustained performance, representing more than eight million units per year according to IQVIA data from October 2025. This growth is accelerated by the increasing number of complex surgical procedures, especially in oncology, and the more frequent use of imaging systems and fluorescence-guided surgery in hospital settings.
Hélène Thomas, deputy CEO of Provepharm (搜索), outlined the company's ambitious vision: "By 2030, our ambition is to be offering an unparalleled range of dyes and to continue innovating to develop their use."
Operational Implementation
Sagent and Provepharm (搜索) are working closely to ensure a seamless transition, maintaining uninterrupted product availability and customer support. The collaboration allows Provepharm to benefit from Sagent's market expertise, in-depth customer knowledge, and significant commercial resources in the U.S. market.
Rothschild & Co (搜索) served as financial advisor to Provepharm (搜索) in structuring and negotiating the commercial partnership with Sagent Pharmaceuticals, highlighting the strategic importance of this alliance in the evolving diagnostic dye market.